Texas Vaccines for Children (TVFC) Program Providers,

As of September 1, 2024, nirsevimab (Beyfortus $^{\text{TM}}$) immunization is available in the Vaccine Allocation and Ordering System (VAOS).

Manufacturer	NDC	Brand	Description
Sanofi Pasteur	49281-0575- 15	Beyfortus (50 mg)	Five Pack: one dose syringe
Sanofi Pasteur	49281-0574- 15	Beyfortus (100 mg)	Five Pack: one dose syringe

Do not administer Beyfortus[™] prior to October 1, 2024, or after March 31, 2025. Beyfortus[™] doses administered prior to October or after April will result in an administration error. Providers must report vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS).

Providers should administer inventory from the 2023–2024 season before requesting additional doses. Providers must store any unused doses after March 31, 2025, until the following RSV season.

Recommendations for Use of Beyfortus™

- DSHS recommends infants aged <8 months born during or entering their first RSV season to receive the following:
 - One dose of 50 mg for infants who weigh <5 kg
 - One dose of 100 mg for infants who weigh ≥5 kg
- Infants aged 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive the following:
 - Two doses of 100 mg of nirsevimab (Beyfortus[™])

TVFC Program Eligibility

Children from birth through 18 years of age who meet one of the following eligibility criteria may receive TVFC vaccines:

- Enrolled in Medicaid or Medicaid-eligible
- Uninsured
- Underinsured
 - Health insurance coverage does not include vaccines
 - Health insurance covers only selected vaccines
 - Health insurance sets a fixed dollar limit or cap on vaccine coverage.

- American Indian or Alaska Native
- Enrolled in the Children's Health Insurance Program (CHIP)

Refer to the following resources for more information on nirsevimab (Beyfortus™) for infants:

- CDC's RSV Prevention Information for Healthcare Providers
- CDC's Immunizations to Protect Infants
- Sanofi's Beyfortus Resources for Healthcare Providers
- AAP's Nirsevimab Frequently Asked Questions

For clinical questions, please contact <u>ImmunizationNurses@dshs.texas.gov</u>. For any questions regarding ordering Beyfortus™, email <u>TXVaccineOrders@dshs.texas.gov</u>. Thank you for your partnership in the TVFC program.

Texas Department of State Health Services Immunization Program